US Patent

US7932268 — Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects

Method of Use · Assigned to University of Pennsylvania Penn · Expires 2027-08-19 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating hyperlipidemia and hypercholesterolemia by administering escalating doses of an MTP inhibitor.

USPTO Abstract

The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1316 lomitapide-mesylate
U-1316 lomitapide-mesylate
U-1316 lomitapide-mesylate
U-1316 lomitapide-mesylate
U-1316 lomitapide-mesylate
U-1316 lomitapide-mesylate
U-1316 lomitapide-mesylate

Patent Metadata

Patent number
US7932268
Jurisdiction
US
Classification
Method of Use
Expires
2027-08-19
Drug substance claim
No
Drug product claim
No
Assignee
University of Pennsylvania Penn
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.